Market access for a healthcare product — whether a medicine, medical device or diagnostic test — involves two complementary objectives: securing recognition of its clinical value and an appropriate reimbursement price in the French market, while anticipating market access requirements across Europe to develop a coherent international pricing strategy.
Market Access for Healthcare Products
Market Access in France: HAS and CEPS
In France, obtaining reimbursement for a healthcare product generally involves two stages: assessment of its clinical value by the French National Authority for Health (HAS), followed by price negotiations with the Economic Committee for Health Products (CEPS).
Although these stages involve different stakeholders and objectives, they must communicate a consistent value proposition to secure the best possible reimbursement conditions.
Economic Committee for Health Products (CEPS)
European Market Access
Beyond the French market, a coherent European market access strategy is essential for two complementary reasons: prices in European reference countries directly influence CEPS negotiations through the European price guarantee clause, while each national market has its own assessment and reimbursement procedures, with timelines and requirements that must be anticipated from the clinical development stage onwards.
Detailed information for this page is currently being prepared.
Find out more → European Market Access (coming soon)